GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Aspira Womens Health Inc (NAS:AWH) » Definitions » Piotroski F-Score

Aspira Womens Health (Aspira Womens Health) Piotroski F-Score : 3 (As of Apr. 28, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Aspira Womens Health Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Aspira Womens Health has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Aspira Womens Health's Piotroski F-Score or its related term are showing as below:

AWH' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 4   Max: 5
Current: 3

During the past 13 years, the highest Piotroski F-Score of Aspira Womens Health was 5. The lowest was 2. And the median was 4.


Aspira Womens Health Piotroski F-Score Historical Data

The historical data trend for Aspira Womens Health's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aspira Womens Health Piotroski F-Score Chart

Aspira Womens Health Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 3.00 5.00 2.00 3.00

Aspira Womens Health Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.00 3.00 2.00 2.00 3.00

Competitive Comparison of Aspira Womens Health's Piotroski F-Score

For the Diagnostics & Research subindustry, Aspira Womens Health's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aspira Womens Health's Piotroski F-Score Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Aspira Womens Health's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Aspira Womens Health's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -6.067 + -2.317 + -4.706 + -3.089 = $-16.18 Mil.
Cash Flow from Operations was -5.706 + -3.417 + -3.321 + -3.45 = $-15.89 Mil.
Revenue was 2.316 + 2.491 + 2.217 + 2.13 = $9.15 Mil.
Gross Profit was 1.191 + 1.55 + 1.307 + 1.219 = $5.27 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(17.373 + 11.496 + 7.72 + 8.662 + 6.262) / 5 = $10.3026 Mil.
Total Assets at the begining of this year (Dec22) was $17.37 Mil.
Long-Term Debt & Capital Lease Obligation was $1.86 Mil.
Total Current Assets was $5.28 Mil.
Total Current Liabilities was $5.12 Mil.
Net Income was -9.268 + -8.243 + -7.783 + -4.591 = $-29.89 Mil.

Revenue was 1.893 + 2.066 + 2.072 + 2.153 = $8.18 Mil.
Gross Profit was 0.961 + 0.966 + 1.156 + 1.24 = $4.32 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(41.079 + 30.861 + 24.016 + 23.942 + 17.373) / 5 = $27.4542 Mil.
Total Assets at the begining of last year (Dec21) was $41.08 Mil.
Long-Term Debt & Capital Lease Obligation was $2.59 Mil.
Total Current Assets was $16.31 Mil.
Total Current Liabilities was $5.53 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Aspira Womens Health's current Net Income (TTM) was -16.18. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Aspira Womens Health's current Cash Flow from Operations (TTM) was -15.89. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-16.179/17.373
=-0.93127266

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-29.885/41.079
=-0.72750067

Aspira Womens Health's return on assets of this year was -0.93127266. Aspira Womens Health's return on assets of last year was -0.72750067. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Aspira Womens Health's current Net Income (TTM) was -16.18. Aspira Womens Health's current Cash Flow from Operations (TTM) was -15.89. ==> -15.89 > -16.18 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=1.857/10.3026
=0.18024576

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=2.587/27.4542
=0.09422966

Aspira Womens Health's gearing of this year was 0.18024576. Aspira Womens Health's gearing of last year was 0.09422966. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=5.28/5.119
=1.03145146

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=16.309/5.527
=2.95078705

Aspira Womens Health's current ratio of this year was 1.03145146. Aspira Womens Health's current ratio of last year was 2.95078705. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Aspira Womens Health's number of shares in issue this year was 10.418. Aspira Womens Health's number of shares in issue last year was 8.306. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=5.267/9.154
=0.57537688

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=4.323/8.184
=0.52822581

Aspira Womens Health's gross margin of this year was 0.57537688. Aspira Womens Health's gross margin of last year was 0.52822581. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=9.154/17.373
=0.52690957

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=8.184/41.079
=0.19922588

Aspira Womens Health's asset turnover of this year was 0.52690957. Aspira Womens Health's asset turnover of last year was 0.19922588. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+0+0+0+1+1
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Aspira Womens Health has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Aspira Womens Health  (NAS:AWH) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Aspira Womens Health Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Aspira Womens Health's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Aspira Womens Health (Aspira Womens Health) Business Description

Traded in Other Exchanges
N/A
Address
12117 Bee Caves Road, Suite 100, Building 3, Austin, TX, USA, 78738
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. The Company markets and sells, 1) Ova1, a blood test intended as an aid to assess the likelihood of malignancy in women with an ovarian adnexal mass for which surgery is planned when the physician's independent clinical and radiological evaluation does not indicate malignancy; (2) Overa, a second-generation biomarker reflex intended to maintain Ova1's high sensitivity while improving specificity; (3) Ova1Plus, a reflex offering which uses Ova1 as the primary test and Overa as a confirmation for Ova1 intermediate range results; and (4) OvaWatch, a lab-developed blood test intended to assist in the initial clinical assessment of malignancy risk in all women with an adnexal mass.
Executives
Nicole Sandford director 12117 BEE CAVES RD BLDG 3, STE 100, AUSTIN TX 78738
Minh Hoang Merchant officer: General Counsel & Secretary 1210 AVONDALE ROAD, HILLSBOROUGH CA 94010
Torsten Hombeck officer: Chief Financial Officer 529 W 42ND ST #6V, NEW YORK NY 10036
Celeste Rachelle Fralick director 2801 MESA ROAD, LUBBOCK TX 79403
Veronica Gh Jordan director C/O ALBANY MOLECULAR RESEARCH, INC., 26 CORPORATE CIRCLE, ALBANY NY 12212-5098
Stefanie L. Cavanaugh director 1120 S CAPITAL OF TX HWY, BLDG 1, STE 300, AUSTIN TX 78746
Ellen O'connor Vos director C/O NTELOS HOLDINGS CORP., 1154 SHENANDOAH VILLAGE DRIVE, WAYNESBORO VA 22980
Jack W Schuler 10 percent owner 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Ryan Thinh Phan officer: CSO & COO 327 CARLTON AVE, LOS GATOS CA 95032
Jannie Prestridge Herchuk director 6331 LAVENDALE AVE, DALLAS TX 75230
Winfred Parnell director 6734 TALMADGE LANE, DALLAS TX 75230
Marlene Mclennan officer: Interim Chief Financial Office 400 SOUTH AUSTRALIAN AVENUE, SUITE 800, WEST PALM BEACH FL 33401
Ruby Sharma director 24 ARNOLD DRIVE, PRINCETON JCT. NJ 08550
Robert D Auerbach director C/O THE COOPER COMPANIES, INC., SUITE 590, PLEASANTON CA 94588
Valerie Barber Palmieri director, officer: President and CEO 63 INDIAN LEDGE RD., MONROE CT 06468

Aspira Womens Health (Aspira Womens Health) Headlines

From GuruFocus

Aspira Women's Health� Reports First Quarter 2023 Financial Results

By sperokesalga sperokesalga 05-11-2023

Aspira Women's Health Announces 1-for-15 Reverse Stock Split

By sperokesalga sperokesalga 05-11-2023